Internal medicine, Cardiovascular disease, UCHealth, Medical Center of the Rockies, Loveland, Colorado, USA.
Internal medicine, Cardiovascular disease, Banner University Medical Center, Phoenix, Arizona, USA.
Catheter Cardiovasc Interv. 2021 Nov 15;98(6):1082-1094. doi: 10.1002/ccd.29394. Epub 2020 Dec 2.
Percutaneous coronary intervention (PCI) is well established for the treatment of obstructive coronary artery disease. This study was performed to assess the impact of in-hospital mortality and 30-day readmission with intracoronary imaging as an adjunct to baseline coronary angiography.
The study was derived from the Healthcare Cost and Utilization Project's National Readmission Database (NRD) of 2016, sponsored by the Agency for Healthcare Research and Quality. Patients who underwent PCI were identified using appropriate ICD-10 codes. Study population was further subcategorized into 2 PCI arms: intravascular imaging (''imaging'' group) and fluoroscopy guided (''angiography'' group). Primary endpoints were 30-day readmissions and in-hospital mortality. Secondary endpoints were length of stay, cost of care, predictors of 30-day readmission and in-hospital mortality in PCI related hospitalizations.
We identified in total 188,368 index admissions, with 12,379 patients in the "imaging-guided" group and 175,989 in the "angiography-alone" group. There were no differences in 30-day readmissions between both groups (~10.8% in both arms, p = .788). However, in-hospital mortality carried a statistically significant reduction with use of imaging-guided PCI (1.72% vs 2.24%, p = .004). The median length of stay was longer in the imaging-guided arm (3 vs. 2 days, p < .001), associated with larger median total hospital costs ($32,123 USD vs. $25,162 USD, p < .001). The strongest predictor of in-hospital mortality in both univariate and multivariate analysis was having an existing coagulopathy.
The results of this study did not confer benefit with regards to 30-day hospital readmission rates when utilizing intracoronary imaging versus angiography-alone in percutaneous coronary intervention, but did suggest there may be an association between the use of intracoronary imaging and improved in-hospital mortality. In addition, resource utilization was higher in the intra-coronary imaging arm of the study.
经皮冠状动脉介入治疗(PCI)已被广泛应用于治疗阻塞性冠状动脉疾病。本研究旨在评估冠状动脉成像作为基线冠状动脉造影的辅助手段对住院期间死亡率和 30 天再入院的影响。
本研究来源于 2016 年由美国医疗保健研究与质量局赞助的医疗保健成本和利用项目国家再入院数据库(NRD)。使用适当的 ICD-10 代码识别接受 PCI 的患者。研究人群进一步分为 2 个 PCI 组:血管内成像(“成像”组)和荧光透视引导(“血管造影”组)。主要终点为 30 天再入院和住院期间死亡率。次要终点为住院时间、护理费用、PCI 相关住院患者 30 天再入院和住院期间死亡率的预测因素。
共确定了 188368 例指数入院,其中“成像引导”组有 12379 例,“血管造影单独”组有 175989 例。两组 30 天再入院率无差异(两组均约为 10.8%,p=0.788)。然而,与血管造影引导 PCI 相比,使用成像引导 PCI 可显著降低住院期间死亡率(1.72%比 2.24%,p=0.004)。成像引导组的中位住院时间较长(3 天比 2 天,p<0.001),中位总住院费用也较大(32123 美元比 25162 美元,p<0.001)。单变量和多变量分析中,住院期间死亡的最强预测因素是存在凝血功能障碍。
本研究结果表明,在经皮冠状动脉介入治疗中使用冠状动脉内成像与单独血管造影相比,并未降低 30 天的住院再入院率,但可能与使用冠状动脉内成像与改善住院期间死亡率之间存在关联。此外,研究中冠状动脉内成像组的资源利用更高。